Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Fresenius USA

This article was originally published in The Gray Sheet

Executive Summary

Fresenius USA: Firm's shareholders will receive approximately 1.112 American Depositary Shares (ADS) of the combined National Medical Care and Fresenius AG business -- Fresenius Medical Care AG -- for each share of Fresenius USA under a plan announced May 8. The plan allows Fresenius USA shareholders to "participate" in the pending combination of Grace's NMC with Fresenius AG ("The Gray Sheet" Feb. 12, p. 8). "Each ADS will evidence one-third of an ordinary share of Fresenius Medical Care AG," Fresenius USA and Fresenius AG say, noting that the exchange ratio is based on "the current intent" that 70 mil. ordinary shares of Fresenius Medical Care AG will be outstanding. After the deal's closing, Fresenius AG, Grace, and Fresenius USA shareholders will hold 50.3%, 44.8%, and 4.9% of the combined business, respectively...

You may also be interested in...

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts